Soiken Holdings Inc. (TYO:2385)
Japan · Delayed Price · Currency is JPY 246.00
-11.00 (-4.28%)
At close: Feb 6, 2026
Soiken Holdings Revenue
Soiken Holdings had revenue of 1.42B JPY in the quarter ending September 30, 2025, with 1.65% growth. This brings the company's revenue in the last twelve months to 4.87B, down -10.23% year-over-year. In the fiscal year ending June 30, 2025, Soiken Holdings had annual revenue of 4.85B, down -6.01%.
Revenue (ttm)
4.87B
Revenue Growth
-10.23%
P/S Ratio
1.32
Revenue / Employee
60.14M
Employees
81
Market Cap
6.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 4.85B | -310.00M | -6.01% |
| Jun 30, 2024 | 5.16B | -2.92B | -36.16% |
| Jun 30, 2023 | 8.08B | -1.27B | -13.57% |
| Jun 30, 2022 | 9.35B | 405.00M | 4.53% |
| Jun 30, 2021 | 8.94B | -370.00M | -3.97% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Linical | 9.87B |
| Kohjin Bio | 5.20B |
| CellSource | 3.71B |
| OncoTherapy Science | 956.00M |
| Chiome Bioscience | 727.99M |
| PRISM BioLab Co.,LTD | 677.00M |
| ADR120S | 49.00M |
| Noile-Immune Biotech | 7.00M |